GSK agreed to license linerixibat to Alfasigma in a deal worth up to $690 million, while Eisai received orphan drug designation in Japan for E2086, a novel selective orexin 2 receptor agonist for narcolepsy.
The FDA has expanded approval of Wakix (pitolisant) to treat cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-controlled substance approved for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06967727 |
Registry and Natural History of Epilepsy-Dyskinesia Syndromes |
RECRUITING | |
| NCT05434728 |
Characterization of Bleeding Disorders in EDS |
UNKNOWN | |
| NCT04734041 |
Integrative Medicine for Hypermobility Spectrum Disorder and Ehlers-Danlos Syndromes (IMforHSDandEDS) |
COMPLETED | NA |
